Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO).

Authors : Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart-Gebhart M
Year : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1558-62

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Authors : Criscitiello C, Azim HA, de Azambuja E, Rubio IT
Year : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 910-1

The landscape of medical oncology in Europe by 2020.

Authors : de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M
Year : 2014
Journal : Ann Oncol
Volume : 25(2)
Pages : 525-8

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer

Authors : Vanderbeeken MC, de Azambuja E
Year : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 27-30

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Authors : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Year : 2013
Journal : Ann Oncol
Volume : 24(5)
Pages : 1203-11

Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.

Authors : Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M
Year : 2013
Journal : Oncologist
Volume : 18(2)
Pages : 134-40

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.

Authors : Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 860-7

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Authors : Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber Rd, Piccart-Gebhart M, Cameron D
Year : 2013
Journal : Lancet Oncol
Volume : 14(3)
Pages : 244-8

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Authors : Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart-Gebhart M, Peccatori FA
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(1)
Pages : 73-9

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Authors : Pinto AC, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Authors : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast
Volume : 22 Suppl 2
Pages : S152-5

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Authors : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Year : 2013
Journal : J Chemother
Volume : 25(4)
Pages : 239-46

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Authors : Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO
Year : 2013
Journal : Breast
Volume : 22(5)
Pages : 606-15

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Authors : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Year : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Clinical practice-changing trials: the HERA study paradigm.

Authors : Zardavas D, Ades F, de Azambuja E
Year : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pages : 1249-56

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Authors : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902